<DOC>
	<DOCNO>NCT00906373</DOCNO>
	<brief_summary>To determine IMC-A12 give combination Sorafenib safe effective patient advance liver cancer .</brief_summary>
	<brief_title>A Study IMC-A12 Combination With Sorafenib Patients With Advanced Cancer Liver</brief_title>
	<detailed_description>The purpose study determine progression free survival ( PFS ) patient unresectable hepatocellular carcinoma receive prior systemic therapy treat IMC-A12 administer every three week combination oral sorafenib administer twice daily .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The patient histologically cytologically confirm , unresectable HCC The patient least one target lesion measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) guideline . Target lesion ( ) must lay within previously irradiate , ablate , chemoembolized area . If lesion lie area , must evidence growth successive imaging study , include tumor hypervascularity , order lesion consider target lesion The patient receive prior systemic therapy HCC . Patients may receive prior embolization , chemoembolization , intraarterial chemotherapy infusion , ethanol injection , radiofrequency ablation , cryosurgery The patient fast serum glucose &lt; 160 mg/dL ULN and/or hemoglobin A1C &lt; 7 % . If baseline nonfasting glucose &lt; 160 mg/dL , fast glucose measurement require The patient ability understand willingness sign write informed consent document The patient brain metastases The patient acute hepatitis The patient poorly control diabetes mellitus . Patients history diabetes mellitus allow participate , provide blood glucose within normal range stable dietary therapeutic regimen condition The patient congestive heart failure &gt; class II NYHA , unstable angina pectoris , new onset angina pectoris , myocardial infarction within past 6 month , cardiac ventricular arrhythmia require antiarrhythmic therapy The patient experience hemorrhage bleed event â‰¥ NCICTCAE Grade 3 within 4 week prior first dose study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>